SLC5A2 and diabetes mellitus: SGLT2 inhibitors also appear safe at low levels of kidney function down to an eGFR of at least 20 mL/min per 1·73 m2 with patients without diabetes being at particularly low risk of ketoacidosis or amputation (whether receiving an SGLT2 inhibitor or not).